Heparin proteoglycans released from rat serosal mast cells inhibit proliferation of rat aortic smooth muscle cells in culture

Circulation Research

Volumn 84, Issue 1, 1999, Pages 74-83

  Wang, Yenfeng ^a   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Heparin proteoglycan; Mast cell; Proliferation; Smooth muscle cell

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; PROTEOHEPARAN SULFATE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; AORTA MEDIA; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; CELL CYCLE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; MALE; MAST CELL DEGRANULATION; MUSCLE FIBER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROSA;

EID: 0033593622     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.1.74     Document Type: Article

References (63)

1. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res. 1986;58:427-444.
2. Benditt EP, Benditt JM. Evidence for a monoclonal origin of the human atherosclerotic plaques. Proc Natl Acad Sci U S A. 1973;70:1753-1756.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
4. Gordon D, Schwartz SM. Replication of arterial smooth muscle cells in hypertension and atherosclerosis. Am J Cardiol. 1987;59:44A-48A.
5. Pickering JG, Weir L, Jekanowski J. Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest. 1993;91: 1469-1480.
6. Mitchinson MJ, Hardwick SJ, Bennett MR. Cell death in atherosclerotic plaques. Curr Opin Lipidol. 1996;7:324-329.
7. Brown BG, Lin JT, Kelsey S, Passamani ER, Levy RI, Dodge HT, Detre KM. Progression of coronary atherosclerosis in patients with probable familial hypercholesterolemia: quantitative arteriographic assessment of patients in NHLBI type II study. Arteriosclerosis. 1989;9:I81-I90.
8. Roederer GO, Langlois YE, Jager KA, Primozich JF, Beach KW, Phillips DJ. Strandness DEJ. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke. 1984;15:605-613.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
10. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol. 1981;90:372-379.
11. Benitz WE, Kelley RT, Anderson CM, Lorant DE, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 1990;2:13-24.
12. Whitelock J, Mitchell S, Underwood PA. The effect of human endothelial cell-derived proteoglycans on human smooth muscle cell growth. Cell Biol Int. 1997;21:181-189.
13. McCaffrey TA, Consigli S, Falcone DJ, Sanborn TA, Spokojny AM, Bush HL Jr. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. J Clin Invest. 1995;96:2667-2675.
14. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90:1669-1678.
15. Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol. 1997;182:115-122.
16. Kaartinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima: functional coupling of exocytosis and phagocytosis in neighboring cells. Arterioscler Thromb Vasc Biol. 1995;15:2047-2054.
17. Wang Y, Lindstedt KA, Kovanen PT. Mast cell granule remnants carry LDL into smooth muscle cells of synthetic phenotype and induce their conversion into foam cells. Arterioscler Thromb Vasc Biol. 1995;15: 801-810.
18. Church MK, Caulfield JP. Mast cell and basophil functions. In: Holgate ST, Church MK, eds. Allergy. London, Gower Medical Publishing; 1993: 5.1-5.12.
19. Kovanen PT. Role of mast cells in atherosclerosis. Chem Immunol. 1995;62:132-170.
20. Yurt RW, Leid RW Jr, Austen KF. Native heparin from rat peritoneal mast cells. J Biol Chem. 1977;252:518-521.
21. Lindstedt KA, Kokkonen JO, Kovanen PT. Soluble heparin proteoglycans released from stimulated mast cells induce uptake of low density lipoproteins by macrophages via scavenger receptor-mediated phagocytosis. J Lipid Res. 1992;33:65-75. 7
22. Rodén L. Highlights in the history of heparin. In: Lane DA, Lindahl U, eds. Heparin. London: Edward Arnold; 1989:1-23
23. Schmidt A, Buddecke E. Bovine arterial smooth muscle cells synthesize two functionally different proteoheparan sulfate species. Exp Cell Res. 1990;189:269-275.
24. Fransson LÅ. The Polysaccharides. New York, NY: Academic Press; 1985:337-415.
25. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980;46:625-634.
26. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest. 1985;52:611-616.
27. Janiszewski M, Laurindo FR, Pasqualucci CA, da Luz PL, Pileggi F. Effects of a single heparin bolus on neointimal growth after arterial injury in intact rabbits. Angiology. 1996;47:549-556.
28. Chan P, Mill S, Mulloy B, Kakkar V, Demoliou-Mason C. Heparin inhibition of human vascular smooth muscle cell hyperplasia. Int Angiol. 1992;11:261-267.
29. Gilbertson JJ, Pettengill OS, Cronenwett JL. Antiproliferative effect of heparin on human smooth muscle cells cultured from intimai hyperplastic lesions of vein grafts. Ann Vasc Surg. 1992;6:265-271.
30. 3H]thymidine incorporation. J Cardiovasc Pharmacol. 1995;25:782-788.
31. Kovanen PT. Mast cells in human fatty streaks and atheromas: implications for intimai lipid accumulation. Curr Opin Lipidol. 1996;7: 281-286.
32. Faris B, Toselli P, Kispert J, Wolfe BL, Pratt CA, Mogayzel PJ, Franzblau C. Elastase effect on the extracellular matrix of rat aortic smooth muscle cells in culture. Exp Mol Pathol. 1986;45:105-117.
33. Chamley JH, Campbell GR, McConnell JD, Gröschel-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tiss Res. 1977;177: 503-522.
34. Castellot JJ Jr, Pukac LA, Caleb BL, Wright TC Jr, Karnovsky MJ. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J Cell Biol. 1989;109:3147-3155.
35. Lindstedt KA. Inhibition of macrophage-mediated low density lipoprotein oxidation by stimulated rat serosal mast cells. J Biol Chem. 1993;268: 7741-7746.
36. Ma H, Kovanen PT. IgE-dependent generation of foam cells: an immune mechanism involving degranulation of sensitized mast cells with resultant uptake of LDL by macrophages. Arterioscler Thromb Vasc Biol. 1995; 15:811-819.
37. Kokkonen JO, Kovanen PT. Low density lipoprotein degradation by rat mast cells: demonstration of extracellular proteolysis caused by mast cell granules. J Biol Chem. 1985;260:14756-14763.
38. Paananen K, Kovanen PT. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J Biol Chem. 1994;269:2023-2031.
39. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid: inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation. 1997;95:1455-1463.
40. Leszczynski D. Regulation of cell cycle and apoptosis by protein kinase C in rat myeloid leukemia cell line. Oncol Res. 1995;7:471-480.
41. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139: 271-279.
42. Taipale J, Koli K, Keski-Oja J. Release of transforming growth factor-β1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem. 1992;267:25378-25384.
43. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem. 1951;193:265-275.
44. Bartold PM, Page RC. A microdetermination method for assaying glycosaminoglycans and proteoglycans. Anal Biochem. 1985;150:320-324.
45. Woodbury RG, Everitt MT, Neurath H. Mast cell proteases. Methods Enzymol. 1981;80:588-609.
46. Letourneur D, Caleb BL, Castellot JJ Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. I. Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol. 1995;165:676-686.
47. Letourneur D, Caleb BL, Castellot JJ Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. II. Degradation and secretion in sensitive and resistant cells. J Cell Physiol. 1995;165: 687-695.
48. Pukac LA, Carter JE, Ottlinger ME, Karnovsky MJ. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J Cell Physiol. 1997;172:69-78.
49. Au YPT, Kenagy RD, Clowes MM, Clowes AW. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 1993;23:177-182.
50. Grainger DJ, Witchell CM, Watson JV, Metcalfe JC, Weissberg PL. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor β-like activity from serum. Cardiovasc Res. 1993;27:2238-2247.
51. 2-macroglobulin inactive complex. J Cell Biol. 1989;109:441-448.
52. Lassila R, Lindstedt KA, Kovanen PT. Native macromolecular heparin proteoglycans exocytosed from stimulated rat serosal mast cells strongly inhibit platelet-collagen interactions. Arterioscler Thromb Vasc Biol. 1997;17:3578-3587.
53. Satoh T, Sugama K, Matsuo A, Kato S, Ro S, Hatanaka M, Sasaguri Y. Histamine as an activator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. Atherosclerosis. 1994; 110:53-61.
54. Hu Z-Q, Yamazaki T, Cai Z, Yoshida T, Shimamura T. Mast cells display natural suppressor activity partially by releasing transforming growth factor-β. Immunology. 1994;82:482-486.
55. Palmberg L, Claesson H, Thyberg J. Effects of leukotrienes on phenotypic properties and growth of arterial smooth muscle cells in primary culture. J Cell Sci. 1989;93:403-408.
56. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol. 1986; 129:11-19.
57. Castellot JJ Jr, Wong K, Herman B, Hoover R, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol. 1985;124:13-20.
58. Wang Y, Lindstedt KA, Kovanen PT. Phagocytosis of mast cell granule remnant-bound LDL by smooth muscle cells of synthetic phenotype: a scavenger receptor-mediated process that effectively stimulates cytoplasmic cholesteryl ester synthesis. J Lipid Res. 1996; 37:2155-2166.
59. Takata K, Horiuchi S, Morino Y. Scavenger receptor-mediated recognition of maleylated albumin and its relation to subsequent endocytic degradation. Biochim Biophys Acta. 1989;984:273-280.
60. Thyberg J, Hedin U, Sjölund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966-990.
61. Campbell JH, Campbell GR. The role of smooth muscle cells in atherosclerosis. Curr Opin Lipidol. 1994;5:323-330.
62. Stein O, Stein Y. Smooth muscle cells and atherosclerosis. Curr Opin Lipidol. 1995;6:269-274.
63. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1084-1088.